Annual report
4579.TEDINET S100VH52
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Amended by S100VJ8W (2025-03-31).
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥213m | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | −¥337m | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | −¥362m | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥293m | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥904m | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥864m | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥528m | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥358m | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥294m | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥495m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥324m | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥723m | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥756m | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥607m | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥495m | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | −¥324m | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥9.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥6.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥6.3bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.2bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.3bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.1bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥752m | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.6bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-12-31d | Cons. | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥4.0bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥181m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥719m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥366m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥289m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥135m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥48m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥279m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥225m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥793m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥30m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-22.87 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.98 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.5 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.07 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.97 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥34.47 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.04 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥253.83 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥281.87 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥261.65 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥227.97 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥190.88 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 57.4% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.7% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.7% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.3% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.1% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 14.1% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.2% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 85 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 67 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 65 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 67 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 70 | at 2020-12-31d | Cons. | Number of employees |
| Operating income | ¥323m | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥478m | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥197m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥445m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥701m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥656m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥550m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥201m | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥445m | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥56m | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥431m | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥584m | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥615m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥655m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.7bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥6.6bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.2bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.4bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥734m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥5.9bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥5.3bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.1bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.3bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥2.6 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.95 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.83 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.34 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-31.26 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥2.6 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.81 | 2022-01-01 → 2022-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥29.31 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥267.27 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥269.95 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥254.49 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥227.47 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥197.12 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.3% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.6% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.5% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.6% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.0% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.5% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.8% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,838,529 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,623,281 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,977,181 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,955,142 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,951,642 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 64 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 64 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 62 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 64 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 1,314
| Item | Context | Value | Unit |
|---|---|---|---|
| Contracted research and development expenses rad | Prior1YearDuration_NonConsolidatedMember | 138217000 | JPY |
| Contracted research and development expenses rad | CurrentYearDuration_NonConsolidatedMember | 120203000 | JPY |
| Clinical trial expense research and development | Prior1YearDuration_NonConsolidatedMember | 151847000 | JPY |
| Clinical trial expense research and development | CurrentYearDuration_NonConsolidatedMember | 116611000 | JPY |
| Depreciation research and development | Prior1YearDuration_NonConsolidatedMember | 168404000 | JPY |
| Depreciation research and development | CurrentYearDuration_NonConsolidatedMember | 177596000 | JPY |
| Directors compensations sga | Prior1YearDuration_NonConsolidatedMember | 63819000 | JPY |
| Directors compensations sga | CurrentYearDuration_NonConsolidatedMember | 64950000 | JPY |
| Salaries and allowances sga other | Prior1YearDuration_NonConsolidatedMember | 141147000 | JPY |
| Salaries and allowances sga other | CurrentYearDuration_NonConsolidatedMember | 149807000 | JPY |
| Business consignment expenses sga other | Prior1YearDuration_NonConsolidatedMember | 142577000 | JPY |
| Business consignment expenses sga other | CurrentYearDuration_NonConsolidatedMember | 221829000 | JPY |
| Patent expense sga other | Prior1YearDuration_NonConsolidatedMember | 68767000 | JPY |
| Patent expense sga other | CurrentYearDuration_NonConsolidatedMember | 61039000 | JPY |
| Depreciation sga other | Prior1YearDuration_NonConsolidatedMember | 6682000 | JPY |
| Depreciation sga other | CurrentYearDuration_NonConsolidatedMember | 6534000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-03-26 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第17期（自 2024年１月１日 至 2024年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ラクオリア創薬株式会社 | |
| Company name in english cover page | FilingDateInstant | RaQualia Pharma Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 須藤 正樹 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)愛知県名古屋市中村区名駅南一丁目21番19号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)052-446-6100（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)財務経理部長 杉山 英史 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)愛知県名古屋市中村区名駅南一丁目21番19号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)052-446-6100（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)財務経理部長 杉山 英史 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E25269 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45790 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ラクオリア創薬株式会社 | |
| Filer name in english | FilingDateInstant | RaQualia Pharma Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-12-31 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |